MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$178,772K
EPS
-$1.08
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
152,169
100,889
103,649*
97,219
General and administrative
29,492
24,387
20,009*
16,673
Total operating expenses
181,661
125,276
123,658
113,892
Loss from operations
-181,661
-125,276
-123,658*
-113,892
Interest income
7,788
8,757
7,208*
8,476
Interest expense
4,595
4,202
1,695*
2,904
Other expense, net
-88
-133
280*
279
Total other income, net
3,105
4,422
5,793*
5,851
Net loss
-178,556
-120,854
-117,866*
-108,041
Unrealized gains (losses) on marketable securities, net
-216
-612
87*
244
Comprehensive loss
-178,772
-121,466
-117,780
-107,797
Basic EPS
-1.08
-0.73
-0.868*
-0.76
Diluted EPS
-1.08
-0.73
-0.868*
-0.76
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$178,772K
(-61.28%↓ Y/Y)
Interest income
$7,788K
(17.55%↑ Y/Y)
Net loss
-$178,556K
(-61.07%↓ Y/Y)
Unrealized gains (losses)
on marketable...
-$216K
(-2063.64%↓ Y/Y)
Total other income,
net
$3,105K
(-37.07%↓ Y/Y)
Interest expense
$4,595K
(4788.30%↑ Y/Y)
Other expense, net
-$88K
(94.49%↑ Y/Y)
Loss from operations
-$181,661K
(-56.89%↓ Y/Y)
Total operating
expenses
$181,661K
(56.89%↑ Y/Y)
Research and development
$152,169K
(53.34%↑ Y/Y)
General and
administrative
$29,492K
(78.15%↑ Y/Y)
Buy us a coffee
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)